Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Confident About Transforming CSU Landscape

And Has High Hopes For CAR-T In Immunology

May 16 2023

• By Kevin Grogan

Novartis — • Source: Novartis

Related Content

Novartis Committed To Carving Out More Indications For Cosentyx

May 12 2023

Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears

Apr 12 2023

Novartis Scores Another CSU Success With Remibrutinib

Oct 01 2021

Novartis’s Ligelizumab Founders In Phase III Despite Positive Predictions

Dec 20 2021

Novartis Debuts Rapidly Manufactured Autologous CAR-Ts

Dec 13 2021

Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities

Jun 30 2022

Related Companies

Novartis AG

Merck KGaA

Sanofi

Roche Holding AG

Additional Topics

Research & Development Strategy Clinical Trials Safety Immune Disorders BioPharmaceutical

More from Immunological

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window